Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

In-Hospital Costs and Costs of Complications of Chronic Total Occlusions

Is a chronic total occlusion worth rechanneling? This question can often be found in different studies, all of them with clinical endpoints. This study (soon to be published in J Am Coll Cardiol Intv.) analyzes another aspect: costs, not only derived from materials used for a successful procedure, but also from materials and hospital stay in case of complications.

Costos hospitalarios y de las complicaciones de las oclusiones totales crónicasResearchers calculated costs for 964 patients, from 12 sites, included in the OPEN-CTO (Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion Hybrid Procedures) registry. Data were collected prospectively. A multivariate model was developed to estimate the higher costs derived from prolonged length of stay due to complications.

 

Mean costs for the index hospitalization were USD 17,048 ± 9904. About 14.5% of patients experienced at least one complication.


Read also: We Must Still Fear the “Big Five Complications” After TAVR.


Obviously, patients with complications had higher hospital costs (about 50% higher) and a 1.5-day longer hospital stay than patients without complications.

 

Seven complications were independently associated with a direct increase of costs and 6 were associated with prolonged stay.

 

Significant perforations and peri-procedural infarctions were the events that increased costs the most.


Read also: El acceso transcavo es seguro en el TAVI.


These costs may entail very different realities depending on where we practice medicine, so there is no possible generalization. Regardless, a cost-benefit analysis beyond money must be applied to all patients. As regards total occlusions, clinical criteria must reign. In cases with high ischemic burden in symptomatic patients, we should at least attempt the procedure, even if it is technically difficult. The opposite case would be a very simple lesion without evident ischemia (no invasive or non-invasive evidence) in an asymptomatic patient. We should avoid falling into the trap of treating such a lesion.

 

Conclusions

Complications have a significant impact on both costs and length of stay (without considering clinical events) for patients undergoing angioplasty for chronic total occlusion. Methods to identify high-risk patients more clearly and to develop strategies to prevent complications may reduce both events and costs.

 

There still are certain angioplasties that we should not even attempt without a careful risk-benefit analysis.

 

Original title: In-Hospital Costs and Costs of Complications of Chronic Total Occlusion Angioplasty. Insights from the OPEN-CTO Registry.

Reference: Adam C. Salisbury et al. J Am Coll Cardiol Intv 2019, article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...